Cell News and Research

RSS

Common gut pathogen increases activity of SMO gene and causes colon tumors

Working with lab cultures and mice, Johns Hopkins scientists have found that a strain of the common gut pathogen Bacteroides fragilis causes colon inflammation and increases activity of a gene called spermine oxidase (SMO) in the intestine.

5 Nov 2011

Opexa reports net loss of $1.30 million for third quarter 2011

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2011 and provided an overview of recent corporate developments.

5 Nov 2011

Heidelberg scientists identify single protein responsible for varicose veins

Dr. Thomas Korff and his group at the Division of Cardiovascular Physiology of Heidelberg University's Institute of Physiology and Pathophysiology have now shown that the pathological remodeling processes causing varicose veins are mediated by a single protein.

5 Nov 2011

Rothman researchers to develop gold standard definition for periprosthetic joint infection

A rise in periprosthetic joint infection (PJI) rates has the orthopedic community moving to develop it's first-ever agreed upon definition and diagnostic criteria to help better treat patients.

5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Osiris Therapeutics third quarter revenues decrease marginally to $10.6 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.

4 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

'Medicine that grows' confronts antibiotics resistance

It's been called "the trots," "Montezuma's Revenge," "the runs" and worse. But no matter the name, when it strikes, victims wish for a medicine that could go straight to the offending bacteria to quickly knock it dead.

4 Nov 2011

Quanticel, Celgene and Versant enter collaboration to discover and develop first-in-class cancer drugs

Privately held biotechnology company Quanticel Pharmaceuticals Inc. and Celgene Corporation, together with Versant Ventures, today announced they have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs.

4 Nov 2011

New technologies could aid in malignant melanoma diagnosis and therapy

Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy.

4 Nov 2011

Brain and cooperation

When Nancy Grace and her partner danced a lively rumba to Spandau Ballet's 1980's hit, "True," on a recent "Dancing with the Stars," more was going on in the legal commentator's brain than worry over a possible wardrobe malfunction. Deep in Grace's cortex, millions of neurons were hard at work doing what they apparently had been built to do: act and react to partner Tristan MacManus's movements to create a pas de deux that had the dancers functioning together (for the most part) like a well-oiled machine.

4 Nov 2011

Cerebellum contributes to creation of cognitive map in the hippocampus

The cerebellum is far more intensively involved in helping us navigate than previously thought. To move and learn effectively in spatial environments our brain, and particularly our hippocampus, creates a "cognitive" map of the environment. The cerebellum contributes to the creation of this map through altering the chemical communication between its neurones. If this ability is inactivated, the brain is no longer able to to create an effective spatial representation and thus navigation in an environment becomes impaired.

4 Nov 2011

Impulsive men have lower levels of GABA in dorsolateral prefrontal cortex

Impulsive individuals tend to display aggressive behavior and have challenges ranging from drug and alcohol abuse, to problem gambling and difficult relationships. They are less able to adapt to different social situations. Impulsivity is also a common feature of psychiatric disorders.

4 Nov 2011

Early diagnosis of large intestine cancer could be feasible in the long term

Itxaro Perez, a biochemist at the University of the Basque Country (UPV/EHU), has contributed in such a way that, in the long term, the early diagnosis of cancer of the large intestine could be feasible.

4 Nov 2011

Inserm researchers successfully rejuvenate cells from elderly donors

Inserm's AVENIR "Genomic plasticity and aging" team, directed by Jean-Marc Lemaitre, Inserm researcher at the Functional Genomics Institute, has recently succeeded in rejuvenating cells from elderly donors.

4 Nov 2011

Important to keep obstacles to malaria control in mind as research moves forward

In a post in the Center for Strategic & International Studies' "Smart Global Health" blog, Julia Nagel, web and social media assistant at the Global Health Policy Center, examines "the obstacles that global malaria control efforts face," writing that "eradicating malaria is complex and difficult" because "there are four species of human malaria" that "respond differently to medicines, exhibit drug resistance in different ways, and most importantly, make finding a fool-proof vaccine against all malaria nearly impossible."

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Einstein scientists receive two NCI grants to study cancer metastasis

The National Cancer Institute (NCI) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $8 million to study the microenvironments that drive the spread of cancer from the primary tumor to other parts of the body in the process known as metastasis.

4 Nov 2011

Pfizer, Sanford-Burnham to partner on translational medicine research

Sanford-Burnham Medical Research Institute is the latest research organization to partner with Pfizer, Inc. as part of Pfizer's commitment to transforming research and development through a focus on translational medicine.

4 Nov 2011

Scientists discover alternative mechanism for extension of telomeres

Scientists of the German Cancer Research Center have discovered an alternative mechanism for the extension of the telomere repeat sequence by DNA repair enzymes.

4 Nov 2011